## Highlights of This Issue 1307

### SPECIAL FEATURES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article, p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1309</td>
<td>Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies</td>
<td>Kim-Hien T. Dao and Jeffrey W. Tyner</td>
<td>1422</td>
</tr>
<tr>
<td>1312</td>
<td>New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma</td>
<td>Riccardo Lencioni</td>
<td>1503</td>
</tr>
</tbody>
</table>

### CCR Translations

- Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies
  - Kim-Hien T. Dao and Jeffrey W. Tyner
  - See article, p. 1422
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
  - Riccardo Lencioni
  - See article, p. 1503

### CCR Perspectives in Drug Approval

- Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?
  - Gilles Vassal, Birgit Geoerger, and Bruce Morland

### Statistics in CCR

- Borrowing Information across Subgroups in Phase II Trials: Is It Useful?
  - Boris Freidlin and Edward L. Korn

### CCR Drug Updates

- Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
  - Jean Hoffman-Censits and Wm. Kevin Kelly

### Molecular Pathways

- Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity
  - Lisa A. Ridnour, Robert Y.S. Cheng, Christopher H. Switzer, Julie L. Heinecke, Stefan Amb, Sharon Glynn, Howard A. Young, Giorgio Trinchieri, and David A. Wink
- Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer
  - Jessica Brownell and Stephen J. Polyak
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yousuke Minami, Shinya Kimura, Taiga Maekawa, Tomoki Naoe, and Kazuma Ohyashiki

See commentary, p. 1309

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. Calvert, Jianghong Deng, David Schiff, Wenhua Xin, Jae K. Lee, Benjamin Purrow, James Christensen, Emanuel Petricoin, and Roger Abounader

Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Kent A. Griffith, Rachel M. Layman, Ian Krop, Lacey A. Paskett, Helen Wong, Lacey E. Dobrolecki, Max S. Wicha, and Jenny C. Chang

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1547</td>
<td>Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer</td>
<td>Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, and Thomas Hellday</td>
</tr>
<tr>
<td>1557</td>
<td>Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study</td>
<td>Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blazkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Emala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, and Dan G. Duda</td>
</tr>
<tr>
<td>1567</td>
<td>Phase I Study of GRN1005 in Recurrent Malignant Glioma</td>
<td>Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom MikkelSEN, Steve Rosenfeld, John Surantopoulos, Christina A. Meyers, Robert M. Fielding, Kelly Elian, Xiaolin Wang, Betty Lawrence, Mona Shing, Stephen Kelsey, Jean Paul Castaigne, and Patrick Y. Wen</td>
</tr>
</tbody>
</table>

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1587</td>
<td>Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer</td>
<td>Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu</td>
</tr>
</tbody>
</table>

**Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients**

Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, and Francois-Clement Bidard

**CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC**

Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcolm V. Brock, Maria I.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

**A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer**


**Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy**

ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4′,6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.